Status: Recruiting
Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma
Safety and Efficacy Evaluation of Tremelimumab Plus Durvalumab(MEDI4736) in Combination with Concurrent Transarterial Chemoembolization in Unresectable Hepatocellular carcinoma
Participants needed: 24
Trial details
Phase: Phase 1, Phase 2Age: 19+Biological sex: AllType: InterventionalSponsor: Yoon Jun KimUpdated: May 14, 2025Locations: 1
Eligibility criteria
1. Capable of giving signed informed consent which includes compliance with the... [+13]
1. Eligible for potentially curative treatment (surgical resection, radiofrequen... [+10]